Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gene Therapy, Open-label, Dose-escalation Study of PF-06838435 (SPK-9001) [Adeno-associated Viral Vector With Human Factor IX Gene] in Subjects With Hemophilia B

NCT02484092 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02484092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02484092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gene Therapy, Open-label, Dose-escalation Study of PF-06838435 (SPK-9001) [Adeno-associated Viral Vector With Human Factor IX Gene] in Subjects With Hemophilia B
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
November 18, 2015
Completion date
April 8, 2019
Enrollment
15 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b